Mesa Laboratories Inc (MLAB)

Currency in USD
127.82
-0.43(-0.34%)
Closed·
122.00-5.82(-4.55%)
·
MLAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
126.54131.87
52 wk Range
69.51144.35
Key Statistics
Prev. Close
128.25
Open
127.11
Day's Range
126.54-131.87
52 wk Range
69.51-144.35
Volume
116.94K
Average Vol. (3m)
128.52K
1-Year Change
56.2019%
Book Value / Share
34.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MLAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
125.00
Downside
-2.21%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Mesa Laboratories Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 125.00
(-2.21% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wells Fargo
Hold110.00-13.94%94.00MaintainAug 14, 2026
Jefferies
Buy130.00+1.71%115.00MaintainMay 29, 2026
Wells Fargo
Hold94.00-26.46%83.00MaintainFeb 04, 2026
Wells Fargo
Hold83.00-35.06%75.00MaintainDec 15, 2025

Mesa Laboratories Inc Earnings Call Summary for Q2/2027

  • Mesa Labs Q2 revenue rose 2.6% to $62.3M, beating estimates, but EPS of $0.75 missed consensus of $1.59 by 53%; shares fell 1.42% after-hours.
  • Gross margin expanded 250bps to 64% YoY; adjusted EBITDA jumped 21.1% to $17.3M driven by improved product mix and operational efficiency gains.
  • Company issued FY2027 guidance of $250M-$255M revenue and $66M-$68M adjusted EBITDA, reflecting Clinical Genomics restructuring for profitability.
  • CEO Kadia announced strategic pivot in Clinical Genomics from growth to profitability; top three customers renewed multi-year contracts representing 25% of segment.
  • Management prioritizing internal investments over M&A, targeting Calibration Solutions expansion, Asia growth, and next-gen Gyrolab platform launch in FY2028.
Last Updated: 11/09/2026, 05:33 PM
Read Full Transcript

Earnings

Latest Release
Nov 09, 2026
EPS / Forecast
0.75 / 1.59
Revenue / Forecast
62.33M / 61.63M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.86
Dividend Yield
0.50%
Industry Median 1.42%
Annualized Payout
0.64
Paid quarterly
5-Years Growth
-
Growth Streak

MLAB Income Statement

Compare MLAB to Peers and Sector

Metrics to compare
MLAB
Peers
Sector
Relationship
P/E Ratio
149.0x23.5x−0.2x
PEG Ratio
0.18−0.090.00
Price / Book
3.8x3.0x2.6x
Price / LTM Sales
2.9x2.9x2.8x
Upside (Analyst Target)
−2.2%30.4%60.9%
Fair Value Upside
Unlock3.1%9.5%Unlock

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment’s products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.10M37.47%268.88M
Other Institutional Investors
3.79M62.53%486.58M
Public Companies & Retail Investors
0.000.00%0.00
Total
5.89M100.00%755.46M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Long Path Smaller Companies Fund, LP8.53%477,12661,191
Long Path Partners, LP8.53%477,12661,191

People Also Watch

44.47
INTA
+1.70%
149.64
SANM
+11.11%
45.70
PENG
+9.25%
68.97
KLIC
+7.75%
59.33
GCT
+1.64%

FAQ

What Is the Mesa Labs (MLAB) Stock Price Today?

The Mesa Labs stock price today is 127.82 USD.

What Stock Exchange Does Mesa Labs Trade On?

Mesa Labs is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Mesa Labs?

The stock symbol for Mesa Labs is "MLAB."

Does Mesa Labs Pay Dividends? What’s The Current Dividend Yield?

The Mesa Labs dividend yield is 0.5%%.

What Is the Mesa Labs Market Cap?

As of today, Mesa Labs market cap is 717.67M USD.

What Is Mesa Labs's Earnings Per Share (TTM)?

The Mesa Labs EPS (TTM) is 0.86.

When Is the Next Mesa Labs Earnings Date?

Mesa Labs will release its next earnings report on Feb 08, 2027.

From a Technical Analysis Perspective, Is MLAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Mesa Labs Stock Split?

Mesa Labs has split 0 times.

How Many Employees Does Mesa Labs Have?

Mesa Labs has 717 employees.

What is the current trading status of Mesa Labs (MLAB)?

As of Nov 10, 2026, Mesa Labs (MLAB) is trading at a price of 127.82 USD, with a previous close of 128.25 USD. The stock has fluctuated within a day range of 126.54 USD to 131.87 USD, while its 52-week range spans from 69.51 USD to 144.35 USD.

What Is Mesa Labs (MLAB) Price Target According to Analysts?

The average 12-month price target for Mesa Labs is 125.00 USD, with a high estimate of 125 USD and a low estimate of 125 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -2.21% Downside potential.

What Is the MLAB Premarket Price?

MLAB's last pre-market stock price is 132.89 USD. The pre-market share volume is 110.00, and the stock has decreased by 4.64, or 3.62%.

What Is the MLAB After Hours Price?

MLAB's last after hours stock price is 122.00 USD, the stock has decreased by -5.82, or -4.55%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.